Loading
SPRY2 (Protein sprouty homolog 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.
Antagonist of fibroblast growth factor (FGF) pathways via inhibition of FGF-mediated phosphorylation of ERK1/2. Thereby acts as an antagonist of FGF-induced retinal lens fibre differentiation, may inhibit limb bud outgrowth and may negatively modulate respiratory organogenesis. Inhibits TGFB-induced epithelial-to-mesenchymal transition in retinal lens epithelial cells.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
In plain words · SPRY2 (Protein sprouty homolog 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.
SPRY2 (Protein sprouty homolog 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.
Antagonist of fibroblast growth factor (FGF) pathways via inhibition of FGF-mediated phosphorylation of ERK1/2.
No product in this corpus aims at SPRY2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA SPRY2: RNA low tissue specificity; high antibody staining in 9 normal tissues; highest cancer staining liver cancer (5 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Gastric & gastro-oesophageal junction cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas SPRY2 tissue; Open Targets ENSG00000136158 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Hacohen et al, Cell, 1998, "Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways". Source.
Sources: HGNC HGNC:11270 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O43597 (protein name, function text, keywords and locations (REST API)); CIViC gene SPRY2 (1 evidence items, 0 assertions, 1 variants; diseases: Gastric Adenocarcinoma (GraphQL API, CC0))
Antagonist of fibroblast growth factor (FGF) pathways via inhibition of FGF-mediated phosphorylation of ERK1/2. Thereby acts as an antagonist of FGF-induced retinal lens fibre differentiation, may inhibit limb bud outgrowth and may negatively modulate respiratory organogenesis. Inhibits TGFB-induced epithelial-to-mesenchymal transition in retinal lens epithelial cells. Inhibits CBL/C-CBL-mediated EGFR ubiquitination. Location: Cytoplasm, cytoskeleton; Cell projection, ruffle membrane (UniProt). Locus 13q31.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adrenal gland, Breast, Bronchus, Caudate, Cerebellum, Cerebral cortex, Cervix, Endometrium.
Medium only: breast cancer, carcinoid, cervical cancer, glioma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SPRY2" OR ABSTRACT:"SPRY2" OR TITLE:"sprouty RTK signaling antagonist 2" OR ABSTRACT:"sprouty RTK signaling antagonist 2" OR TITLE:"Protein sprouty homolog 2" OR ABSTRACT:"Protein sprouty homolog 2" OR TITLE:"hSPRY2" OR ABSTRACT:"hSPRY2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SPRY2, not a curated reading list.